Company profile: BioIVT
1.1 - Company Overview
Company description
- Provider of biological and in vitro products and services for biopharmaceutical, diagnostic, and biotechnology organizations. Offerings include in vivo ADME/PK studies, bioanalytical services, biospecimen characterization, consulting for drug R&D, long-term hepatocyte culture systems (HEPATOPAC and HEPATOMUNE), and Human AB Serum for cell culture.
Products and services
- HEPATOPAC® and HEPATOMUNE® Cultures: Long-term hepatocyte culture systems for drug safety, metabolism, and efficacy research in liver cell models
- In Vivo ADME & PK Studies: In vivo services characterize radiolabeled compound synthesis, tissue distribution, metabolite identification (Met ID), excretion profiles, pharmacokinetics, and plasma protein binding
- Bioanalytical Services: Method-validated assays deliver in vivo metabolite identification, small molecule and intermediate molecule analysis, toxicokinetic (TK) analysis, and method validation & qualification
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioIVT
Quantgene
HQ: United States
Website
- Description: Provider of genomics and AI solutions in cancer diagnostics and liquid biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantgene company profile →
Lexicon Pharmaceuticals
HQ: United States
Website
- Description: Provider of precise medicines for human disease, including INPEFA (sotagliflozin), a once-daily oral tablet that reduces the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. Pipeline includes LX9211 for DPNP (AAK1) and sotagliflozin for type 1 diabetes (US regulatory) and HCM (preclinical).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexicon Pharmaceuticals company profile →
SCIEX
HQ: United States
Website
- Description: Provider of mass spectrometry, capillary electrophoresis, ion sources, in vitro diagnostics, HPLC and mobility spectrometry solutions for research, drug discovery and development, clinical research, and food and environmental testing. Portfolio includes Triple Quad, QTRAP, X-Series QTOF, ZenoTOF 7600, Echo MS, and TripleTOF systems supporting qualitative and quantitative analyses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SCIEX company profile →
Nextcode
HQ: United States
Website
- Description: Provider of sequence-based clinical diagnostics and genome interpretation solutions that address big data challenges, leveraging technology developed over more than 16 years at deCODE genetics to enable the widespread incorporation of genome sequence data into patient diagnosis and care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nextcode company profile →
DNAfit
HQ: United Kingdom
Website
- Description: Provider of at-home DNA testing and genetic insights for health, fitness, and nutrition. Offerings include CircleDNA Premium (500+ reports via saliva swab), genetic carrier screening, disease and cancer risk overviews, diet and fitness reports, skin predisposition insights, and success trait summaries to help personalize exercise, nutrition, and skincare choices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNAfit company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioIVT
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioIVT
2.2 - Growth funds investing in similar companies to BioIVT
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioIVT
4.2 - Public trading comparable groups for BioIVT
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →